Skip to main content
news
REUTERS/Tingshu Wang

Cooley, CYL & Partners and DeHeng Law Offices have advised China’s Asymchem Laboratories on its HK$6.85 billion ($878 million) secondary listing in Hong Kong, with Latham & Watkins and JunHe representing the joint sponsors.

This is believed to be the biggest healthcare IPO in Hong Kong this year. The company has been listed on the Shenzhen Stock Exchange since 2016.

Asymchem is a Chinese contract development manufacturing organisation (CDMO) serving the global pharmaceutical industry. According to Frost & Sullivan, it is the world’s fifth-largest drug substance CDMO by revenue, and the largest China-based commercial stage chemical drug CDMO.

The Cooley team was led by partners Yiming Liu and Michael Yu.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

R&T guides VietJet on historic $8 bln aviation deal

by Nimitt Dixit |

Singapore’s Rajah & Tann has advised Vietnam's VietJet Air on reaffirmation of its $8 billion deal with CFM International to acquire over 400 CFM advanced Leap 1B Aircraft Engines.

Deals

Davis Polk, Gibson Dunn advise on $2.3 bln Nippon Paint-AOC deal

by Asian Legal Business《亚洲法律杂志》 |

Davis Polk & Wardwell has advised Japanese paint manufacturer Nippon Paint on its $2.3 billion acquisition of U.S. chemicals formulator AOC from Lone Star Funds, which was represented by Gibson, Dunn & Crutcher.

Deals

Stephenson Harwood, Links advise on $349 mln SG-UK taxi deal

by Asian Legal Business《亚洲法律杂志》 |

Stephenson Harwood has advised Singaporean transport operator ComfortDelGro on its 269-million-pound ($349 million) acquisition of the British private hire cab and courier company Addison Lee, whose shareholders were represented by Linklaters.